Key result
Novel biomarkers combined with CCTA may improve risk stratification beyond traditional predictors in stable angina.
This review discusses the clinical utility of novel inflammatory serum and imaging biomarkers for risk stratification in patients with stable angina.
May support multimarker-CCTA panels for stable angina stratification; leaves open prospective validation before practice change.
Inflammatory mediators appear to be the most intriguing yet confusing subject, regarding the management of patients with acute coronary syndromes (ACS). The current inflammatory concept of atherosclerotic coronary artery disease (CAD) led many investigators to concentrate on systemic markers of inflammation, as well as imaging techniques, which may be helpful in risk stratification and prognosis assessment for cardiovascular events. In this review, we try to depict many of the recently studied markers regarding stable angina (SA), their clinical usefulness, and possible future applications in the field.
No takes yet. Share an insight, caveat, or question.
Tsaknis et al. (2014) conducted a review in Stable Angina. Novel serum and imaging biomarkers was evaluated. A combination of novel serum biomarkers and advanced imaging modalities, such as CCTA, may provide incremental prognostic value over traditional clinical predictors for risk stratification in stable angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: